Literature DB >> 25205666

Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Aaron D Fox1, Adam Chamberlain2, Nancy L Sohler3, Taeko Frost4, Chinazo O Cunningham5.   

Abstract

Poor access to buprenorphine maintenance treatment (BMT) may contribute to illicit buprenorphine use. This study investigated illicit buprenorphine use and barriers to BMT among syringe exchange participants. Computer-based interviews conducted at a New York City harm reduction agency determined: prior buprenorphine use; barriers to BMT; and interest in BMT. Of 102 opioid users, 57 had used illicit buprenorphine and 32 had used prescribed buprenorphine. When illicit buprenorphine users were compared to non-users: barriers to BMT ("did not know where to get treatment") were more common (64 vs. 36%, p<0.01); mean levels of interest in BMT were greater (3.37 ± 1.29 vs. 2.80 ± 1.34, p=0.03); and more participants reported themselves likely to initiate treatment (82 vs. 50%, p<0.01). Illicit buprenorphine users were interested in BMT but did not know where to go for treatment. Addressing barriers to BMT could reduce illicit buprenorphine use.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Access to care; Buprenorphine; Opioid addiction; Syringe exchange

Mesh:

Substances:

Year:  2014        PMID: 25205666      PMCID: PMC4250323          DOI: 10.1016/j.jsat.2014.07.015

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  32 in total

1.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

2.  Diversion of buprenorphine/naloxone coformulated tablets in a region with high prescribing prevalence.

Authors:  Andrew A Monte; Todd Mandell; Bonnie B Wilford; Joseph Tennyson; Edward W Boyer
Journal:  J Addict Dis       Date:  2009-07

3.  Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.

Authors:  Chris-Ellyn Johanson; Cynthia L Arfken; Salvatore di Menza; Charles Roberts Schuster
Journal:  Drug Alcohol Depend       Date:  2011-08-21       Impact factor: 4.492

4.  Post-marketing surveillance of methadone and buprenorphine in the United States.

Authors:  Nabarun Dasgupta; Elise J Bailey; Theodore Cicero; James Inciardi; Mark Parrino; Andrew Rosenblum; Richard C Dart
Journal:  Pain Med       Date:  2010-06-08       Impact factor: 3.750

5.  The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: recent service utilization trends in the use of buprenorphine and methadone.

Authors:  Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer
Journal:  Drug Alcohol Depend       Date:  2011-11-16       Impact factor: 4.492

6.  I heard about it from a friend: assessing interest in buprenorphine treatment.

Authors:  Aaron D Fox; Pooja A Shah; Nancy L Sohler; Carolina M Lopez; Joanna L Starrels; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

Review 7.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Authors:  R P Mattick; J Kimber; C Breen; M Davoli
Journal:  Cochrane Database Syst Rev       Date:  2008-04-16

8.  Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.

Authors:  Shannon Gwin Mitchell; Sharon M Kelly; Barry S Brown; Heather Schacht Reisinger; James A Peterson; Adrienne Ruhf; Michael H Agar; Kevin E O'Grady; Robert P Schwartz
Journal:  Am J Addict       Date:  2009 Sep-Oct

9.  Prior buprenorphine experience is associated with office-based buprenorphine treatment outcomes.

Authors:  Chinazo O Cunningham; Robert J Roose; Joanna L Starrels; Angela Giovanniello; Nancy L Sohler
Journal:  J Addict Med       Date:  2013 Jul-Aug       Impact factor: 3.702

10.  Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems.

Authors:  Theresa A Rowe; Janet S Jacapraro; Darius A Rastegar
Journal:  Addict Sci Clin Pract       Date:  2012-10-29
View more
  18 in total

1.  Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.

Authors:  Aaron D Fox; Adam Chamberlain; Taeko Frost; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2015       Impact factor: 3.716

2.  Buprenorphine shared medical appointments for the treatment of opioid dependence in a homeless clinic.

Authors:  Sara L Doorley; Cheryl J Ho; Elizabeth Echeverria; Charles Preston; Huy Ngo; Ahmad Kamal; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2016-11-29       Impact factor: 3.716

Review 3.  Update on Barriers to Pharmacotherapy for Opioid Use Disorders.

Authors:  Anjalee Sharma; Sharon M Kelly; Shannon Gwin Mitchell; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz
Journal:  Curr Psychiatry Rep       Date:  2017-06       Impact factor: 5.285

4.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

5.  Supporting individuals using medications for opioid use disorder in recovery residences: challenges and opportunities for addressing the opioid epidemic.

Authors:  Jennifer Miles; Jason Howell; Dave Sheridan; George Braucht; Amy Mericle
Journal:  Am J Drug Alcohol Abuse       Date:  2020-02-24       Impact factor: 3.829

6.  Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.

Authors:  Raminta Daniulaityte; Ramzi W Nahhas; Sydney Silverstein; Silvia Martins; Angela Zaragoza; Avery Moeller; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-09-22       Impact factor: 4.492

7.  Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast.

Authors:  Pablo K Valente; Angela R Bazzi; Ellen Childs; Peter Salhaney; Joel Earlywine; Jennifer Olson; Dea L Biancarelli; Brandon D L Marshall; Katie B Biello
Journal:  Int J Drug Policy       Date:  2020-09-07

8.  Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky.

Authors:  Hannah Lf Cooper; David H Cloud; Patricia R Freeman; Monica Fadanelli; Travis Green; Connor Van Meter; Stephanie Beane; Umedjon Ibragimov; April M Young
Journal:  Int J Drug Policy       Date:  2020-03-26

Review 9.  Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.

Authors:  Katherine Mackey; Stephanie Veazie; Johanna Anderson; Donald Bourne; Kim Peterson
Journal:  J Gen Intern Med       Date:  2020-11-03       Impact factor: 5.128

10.  Impact of a jail-based treatment decision-making intervention on post-release initiation of medications for opioid use disorder.

Authors:  C J Banta-Green; J R Williams; J M Sears; A S Floyd; J I Tsui; T J Hoeft
Journal:  Drug Alcohol Depend       Date:  2019-12-11       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.